Mepolizumab as a successful steroid-sparing agent in two patients with idiopathic hypereosinophilic syndrome (iHES)

Off-label coverage of mepolizumab 100 mg q 4 weeks was approved. Since starting mepolizumab 6 months ago, her eosinophil count decreased to zero and so far, prednisone has been weaned to 5 mg daily with normalization of LFTs, maintenance of disease control and desired 22 pound weight loss. Since sta...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB278-AB278
Hauptverfasser:	Guo, Canting, Bochner, Bruce S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Leukocytes (eosinophilic) Monoclonal antibodies Patients Weaning
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!